news Scientists stress need for research into COVID-19 symptom treatment 15 May 2020 | By Victoria Rees (Drug Target Review) In a new article, researchers highlight the need for treatments to combat the potentially lethal overreaction of the immune system in the progression of COVID-19.
news Researchers observe how SARS-CoV-2 changes human cells after infection, revealing drug targets 15 May 2020 | By Victoria Rees (Drug Target Review) Using mass spectrometry, researchers have shown how human cells are changed by infection from SARS-CoV-2, allowing the team to identify drug targets to prevent viral reproduction.
news Researchers find TMPRSS2 and TMPRSS4 enable SARS-CoV-2 infection of digestive system 14 May 2020 | By Victoria Rees (Drug Target Review) A group of researchers has found that SARS-CoV-2 may not spread by faecal-to-oral transmission, but is able to infect the gastrointestinal tract via the TMPRSS2 and TMPRSS4 enzymes.
news Combination of two neutralising antibodies suggested as COVID-19 treatment 14 May 2020 | By Victoria Rees (Drug Target Review) Two antibodies named B38 and H4 could work as a COVID-19 therapeutic by neutralising the virus, say researchers in China.
whitepaper ebook: High-content analysis and infectious disease 12 May 2020 | By PerkinElmer Learn how you could use high-content analysis for functional & phenotypic assays in your infectious disease research or drug discovery.
news Procedure developed to create murine models of COVID-19 for testing of therapeutics and vaccines 12 May 2020 | By Victoria Rees (Drug Target Review) Russian researchers have created a process for the development of mouse models for use in pre-clinical studies of COVID-19 treatments and vaccines.
news Molecules derived from ticks could be used as late-stage COVID-19 treatment 12 May 2020 | By Victoria Rees (Drug Target Review) Researchers have found that molecules from ticks called Evasins have the potential to halt cytokine storms, the leading cause of COVID-19 fatalities.
news Multivalent carbohydrate-binding modules show efficacy against COVID-19 8 May 2020 | By Victoria Rees (Drug Target Review) Tested on plaque reducing assays, researchers have identified a lead candidate multivalent carbohydrate-binding module for the treatment of COVID-19.
news Study finds activation sequence of COVID-19 S protein is cleaved by furin protease 6 May 2020 | By Victoria Rees (Drug Target Review) Researchers have shown that the activation sequence the SARS-CoV-2 S protein is cleaved by the cellular enzyme furin which is also required for the infection of lung cells.
news Researchers identify monoclonal antibody to neutralise COVID-19 5 May 2020 | By Victoria Rees (Drug Target Review) An antibody that neutralises both SARS-CoV and SARS-CoV-2 in cell cultures has been discovered by researchers and could be used to treat COVID-19.
news Mass spec used to reveal glycan structures of COVID-19 Spike protein 5 May 2020 | By Victoria Rees (Drug Target Review) High-resolution mass spectrometry has been used by researchers to map the glycan-processing states of the Spike protein of the SARS-CoV-2 virus, which causes COVID-19.
news Cytokine storms and T-cell counts may offer clues on COVID-19 treatment 4 May 2020 | By Victoria Rees (Drug Target Review) According to a new study, treatments for COVID-19 should focus on cytokines and T-cell counts and their function, rather than patient respiratory function.
article Intravenous immunoglobulins, hyperimmunes and pandemic viruses 4 May 2020 | By Hannah Balfour (Drug Target Review) David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
news Researchers reveal cryo-EM structure of remdesivir bound to SARS-CoV-2 4 May 2020 | By Victoria Rees (Drug Target Review) A group of researchers has used cryo-EM to discover the structure of the remdesivir-bound RNA complex of SARS-CoV-2 and explain how the drug inhibits COVID-19 viral replication.
news Researchers suggest COVID-19 therapeutics needed to target blood vessel leakage 1 May 2020 | By Victoria Rees (Drug Target Review) According to researchers, ACE2 receptors disappear from lung cells during COVID-19, allowing small blood vessels to leak at the site of infection, presenting a new drug target.
